A Study of LY3471851 in Participants With Eczema
Public ClinicalTrials.gov record NCT04081350. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to learn more about the safety and side effects of LY3471851 when given by injection just under the skin to participants with eczema. The study will last up to 48 weeks and may include up to 23 visits to the study center.
Study identification
- NCT ID
- NCT04081350
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 3, 2019
- Primary completion
- Jun 23, 2022
- Completion
- Jun 23, 2022
- Last update posted
- Feb 19, 2024
2019 – 2022
United States locations
- U.S. sites
- 20
- U.S. states
- 12
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arkansas Research Trials, LLC | North Little Rock | Arkansas | 72117 | — |
| California Dermatology & Clinical Research Institute | Encinitas | California | 92024 | — |
| Center For Dermatology Clinical Research, Inc. | Fremont | California | 94538 | — |
| Therapeutics Clinical Research | San Diego | California | 92123 | — |
| Clinical Science Institute | Santa Monica | California | 90404 | — |
| Miami Dermatology and Laser Research | Miami | Florida | 33173 | — |
| ForCare Clinical Research | Tampa | Florida | 33613-1244 | — |
| Medical Dermatology Specialists | Sandy Springs | Georgia | 30328 | — |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana | 46250 | — |
| Skin Sciences | Louisville | Kentucky | 40217 | — |
| Derm Center | Troy | Michigan | 48084 | — |
| ActivMed Practices and Research | Portsmouth | New Hampshire | 03801 | — |
| Remington-Davis, Inc | Columbus | Ohio | 43215 | — |
| Unity Clinical Research | Oklahoma City | Oklahoma | 73118 | — |
| Paddington Testing Company Inc | Philadelphia | Pennsylvania | 19103 | — |
| DermDox Centers for Dermatology | Sugarloaf | Pennsylvania | 18249 | — |
| Studies in Dermatology, LLC | Cypress | Texas | 77433 | — |
| Rodgers Dermatology | Frisco | Texas | 75034 | — |
| Progressive Clinical Research | San Antonio | Texas | 78213 | — |
| Complete Dermatology | Sugar Land | Texas | 77478 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Dermatitis, Atopic trials
Other public records listing Dermatitis, Atopic. Sorted by last update posted; newest first. Not a recommendation.
- NCT07599813: A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis Recruiting
- NCT07230860: A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis Recruiting
- NCT06241118: A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor Recruiting
- NCT01631617: Effects of Treatments on Atopic Dermatitis Recruiting
- NCT05769777: Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis Active, not recruiting
- NCT06899204: Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04081350, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 19, 2024 · Synced Sep 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04081350 live on ClinicalTrials.gov.